Amgen Inc.
At today's price, Amgen Inc. (AMGN) is priced for +5.8% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Amgen has rebuilt its growth around a handful of newer products: its six key growth drivers grew 24% year over year and generated $5.6 billion in the most recent quarter, almost 70% of total product sales, which is the engine carrying the company past its older, patent-exposed franchises. • The largest single risk is the balance sheet behind that growth: net debt sits near $45 billion, roughly 4.3 times operating income, with interest coverage under 4 times, a load taken on for acquisition and
Is AMGN overvalued? See what's priced in →
3,057 institutional managers reported holding AMGN in 13F filings for the quarter ended 2026-03-31. Together they hold about 77% of the company; the top 10 hold 42%. 177 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 12.2M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (4.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
AMGN has cut its share count 5.8% over the past five years, spending $8.88B on repurchases. It pays a dividend, and has for 15 years running, raised 14 years straight; the current rate is $9.66 a share annually. Cash returned over the past three years: $13.59B in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at AMGN over the trailing three years. Absence is a fact about the company, not a signal. 22 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
AMGN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | +5.5% | +9.9% |
| 2023-11-01 | -0.9% | +15.3% |
| 2024-02-15 | -8.1% | -9.1% |
| 2024-05-04 | +12.2% | -0.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
AMGN's latest 8-K filings: 2026-05-20 (items 5.07); 2026-05-19 (items 5.02); 2026-04-30 (items 2.02, 9.01); 2026-04-22 (items 5.02, 9.01); 2026-02-19 (items 1.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.